Calculating The Indirect Costs Of Adult Pneumococcal Disease And The Rate Of Return To The 13-Valent Pneumococcal Conjugate Vaccine (PCV13) In Older Adults, With An Application To Denmark

Sevilla, Jaypee; Stawasz, Andrew; Burnes, Daria; Poulsen, PB; Satō, Reiko; De, Bloom

doi:10.1016/j.jval.2017.08.2302

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In general, the literature on this topic is not numerous, although research has been found from Denmark, Switzerland, Turkey or the United States. [19,20,21,22] The US authors indicate that vaccinations against pneumococcus allow savings in indirect costs exceeding 70% savings in direct costs. [22] According to the Turkish researchers, indirect costs account for 21%, 26% and 84% of of pneumococcal meningitis, pneumonia and OM total costs, respectively.…”

Section: Discussionmentioning

confidence: 99%

Indirect costs of pneumococcal diseases in Poland: estimation based on the data of the Social Insurance Institution (ZUS) regarding sickness absence

Golicki,

Jaśkowiak,

Dobrowolska

et al. 2019

Journal of Health Policy &Amp; Outcomes Research

View full text Add to dashboard Cite

Background: The study aimed to estimate the indirect costs of pneumococcal diseases in Poland based on the data of the Social Insurance Institution (ZUS) regarding sickness absence. Methods: The study included the following diseases, which may be caused by Streptococcus pneumoniae: meningitis, sepsis, pneumonia and otitis media (OM). Indirect costs resulting from adults’ sick leave for their own sickness or for caring for a sick child were taken into account. The ZUS data concerning all diagnoses of the analysed diseases, regardless of the aetiology, was used. The data was corrected for the share of cases caused by S. pneumoniae, determined based on epidemiological data found in the literature. Epidemiological data were searched in the following databases: MEDLINE, Polska Bibliografia Lekarska and on the NIZP-PZH website. The unit cost of lost productivity was estimated based on the methodology recommended by AOTMiT HTA guidelines (2016), including methods suggested in the EY (2013) and INFARMA (2014) reports. Results: Total absenteeism due to pneumococcal diseases amounted to approx. 302,000 days, of which 156,000 days were absences due to own illness and 146,000 days because of child care. The total indirect costs of absenteeism due to diseases caused by S. pneumoniae amounted to approx. PLN 95.5 million, of which PLN 49.4 million were the costs of diseases in the adult population (including 90% of pneumococcal pneumonia), and 46.1 PLN million costs resulting from children's diseases (in 57% and 42%, respectively, costs of OM and pneumonia). Conclusions: Diseases with pneumococcal aetiology are the cause of a significant number of sickness absence and indirect costs arising from them are at a level similar to the costs of purchasing vaccines for the universal pneumococcal vaccination program.

show abstract

Section: Discussionmentioning

confidence: 99%

Indirect costs of pneumococcal diseases in Poland: estimation based on the data of the Social Insurance Institution (ZUS) regarding sickness absence

Golicki,

Jaśkowiak,

Dobrowolska

et al. 2019

Journal of Health Policy &Amp; Outcomes Research

View full text Add to dashboard Cite

show abstract

“… Country Author (Ref.) Analysis type Intervention Comparator Assessment Austria Walter et al 110 BIM PCV13 or PPV23 None Positive Belgium Marbaix et al 71 CUA PCV13 None Positive Belgium Willem et al 112 CUA PPV23 PCV13+PPV23 Positive Denmark Sevilla et al 95 CA PCV13 NR Positive Denmark Birck et al 41 CEA PPV23 None Positive EU* Esposito et al 52 CA NR NR Positive Finland THL 103 CEA NR NR NR France HCSP 59 CUA PCV13+PPV23 PPV23 Positive Germany Kuchenbecker et al 67 <...…”

Section: Health Economic Evidencementioning

confidence: 99%

Recent changes to adult national immunization programs for pneumococcal vaccination in Europe and how they impact coverage: A systematic review of published and grey literature

Arya,

Norton,

Kaushik

et al. 2023

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Despite widespread use of pneumococcal vaccines throughout Europe, the burden of pneumococcal disease (PD) in adults is considerable. To mitigate this burden, National Immunization Technical Advisory Groups (NITAGs) and Health Technology Assessment (HTA) agencies assess the value of different vaccine schedules for protecting against PD. The aim of this review was to assess the evidence and rationales used by NITAGs/HTA agencies, when considering recent changes to National Immunization Programs (NIPs) for adults, and how identified changes affected vaccine coverage rates (VCRs). A systematic review was conducted of published literature from PubMed® and Embase®, and gray literature from HTA/NITAG websites from the last 5 y, covering 31 European countries. Evidence related to NIP recommendations, epidemiology (invasive PD, pneumonia), health economic assessments and VCRs were collected and synthesized. Eighty-four records providing data for 26 countries were identified. Of these, eight described explicit changes to NIPs for adults in seven countries. Despite data gaps, some trends were observed; first, there appears to be a convergence of NIP recommendations in many countries toward sequential vaccination, with a pneumococcal conjugate vaccine (PCV), followed by pneumococcal polysaccharide vaccine 23. Second, reducing economic or healthcare burden were common rationales for implementing changes. Third, most health economic analyses assessing higher-valency PCVs for adults found its inclusion in NIPs cost-effective. Finally, higher coverage rates were seen in most cases where countries had expanded their NIPs to cover at-risk populations. The findings can encourage agencies to improve surveillance systems and work to reach the NIP’s target populations more effectively.

show abstract

“…While MenB's education-related costs can lead to losses in lifetime productivity, MenB can also impact productivity more directly when its burdens extend into working ages. MenB can lead to missed workdays and can hinder productivity while at work (94,99). All of this can lead to missed opportunities for work-related skill development or career advancement.…”

Section: Labor Market Productivity Gainsmentioning

confidence: 99%

“…In addition to market productivity, which involves paid work, MenB also impacts non-market productivity, which involves unpaid work. Specifically, MenB can impact patients' ability to spend time volunteering, caregiving, and doing housework and can impact their productivity while working on such activities (99).…”

Section: Non-market Productivity and Leisure Gainsmentioning

confidence: 99%

Health Technology Assessment for Vaccines Against Rare, Severe Infections: Properly Accounting for Serogroup B Meningococcal Vaccination's Full Social and Economic Benefits

Stawasz

Huang

Kirby

et al. 2020

Front. Public Health

View full text Add to dashboard Cite

The high price of new generations of vaccines relative to their predecessors has become an important consideration in debates over whether the benefits of the new vaccines justify their costs. An increasingly central line of inquiry in the literature on valuing vaccination surrounds accounting for the full social and economic benefits of vaccination. This paper applies this emerging perspective to the particular case of vaccination against serogroup B meningococcal disease (MenB). We explore key issues involved in health technology assessments of MenB vaccination, which have led to pronounced heterogeneity in evaluation methods and recommendation outcomes across countries such as France, Germany, the US, and the UK. Accounting for typically neglected sources of socioeconomic benefit could potentially impact recommendation and reimbursement decisions. We propose a taxonomy of such benefits built around four dimensions: (i) internalized health benefits, (ii) internalized non-health benefits, (iii) externalized health benefits, and (iv) externalized non-health benefits. This approach offers a systematic, comprehensive evaluation framework that can be used in future assessment of MenB vaccines as well as other health technologies.

show abstract

Calculating The Indirect Costs Of Adult Pneumococcal Disease And The Rate Of Return To The 13-Valent Pneumococcal Conjugate Vaccine (PCV13) In Older Adults, With An Application To Denmark

Cited by 3 publications

References 0 publications

Indirect costs of pneumococcal diseases in Poland: estimation based on the data of the Social Insurance Institution (ZUS) regarding sickness absence

Indirect costs of pneumococcal diseases in Poland: estimation based on the data of the Social Insurance Institution (ZUS) regarding sickness absence

Recent changes to adult national immunization programs for pneumococcal vaccination in Europe and how they impact coverage: A systematic review of published and grey literature

Health Technology Assessment for Vaccines Against Rare, Severe Infections: Properly Accounting for Serogroup B Meningococcal Vaccination's Full Social and Economic Benefits

Contact Info

Product

Resources

About